Center for HUS Prevention Control and Management at the Pediatric Nephrology, Dialysis and Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 9, 20122, Milano, Italy.
Kidney Transplant Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Pediatr Nephrol. 2021 Sep;36(9):2891-2894. doi: 10.1007/s00467-021-05127-3. Epub 2021 May 17.
Fenoldopam, a vasodilating agent, may represent a potential therapeutic opportunity to increase renal perfusion in those conditions where renal hemodynamics are severely impaired by vascular sub-occlusion, as, indeed, is the case in thrombotic microangiopathies.
The renal resistance index (RRI) was measured, on and off fenoldopam, in 27 children with STEC-HUS.
A 12% decrease in RRI was observed on fenoldopam compared to off treatment without changes in the systemic hemodynamics and with no side effects.
If confirmed in larger series, fenoldopam may become an important addition to supportive care to reduce ischemic damage in STEC-HUS and improve long-term outcomes.
芬多拉唑是一种血管扩张剂，可能为那些因血管阻塞而严重受损的情况下增加肾灌注提供潜在的治疗机会，血栓性微血管病确实就是这种情况。
在 27 例 STEC-HUS 患儿中测量了芬多拉唑开和关时的肾阻力指数（RRI）。
与停药相比，芬多拉唑使 RRI 下降 12%，而全身血流动力学无变化且无副作用。
如果在更大的系列中得到证实，芬多拉唑可能成为支持性治疗的重要补充，以减少 STEC-HUS 的缺血性损伤并改善长期结局。
